Pyruvate kinase deficiency (PKD) is a rare genetic disorder that leads to chronic hemolytic anemia, a condition where red blood cells are destroyed faster than they can be made. This deficiency is ...

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...

PYRUKYND received FDA approval for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in February 2022. The drug generated product revenue of $26.8 million for the ...

The study uncovers a novel mechanism by which ING5 promotes the phosphorylation of pyruvate dehydrogenase kinase 1 (PDK1) at tyrosine 163 (Y163), thereby inhibiting the Warburg effect and reducing ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

How two classmates reconnected to help close a $131.8 million pharma deal ...